ENTA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -151.71% compared to Enanta Pharmaceuticals's net margin of -49.65%. Enanta Pharmaceuticals's return on equity of -74.26% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Enanta Pharmaceuticals has a consensus price target of $14.83, signalling upside risk potential of 154.87%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.23%. Given that Enanta Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe Enanta Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

Enanta Pharmaceuticals has a beta of 0.811, which suggesting that the stock is 18.902% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals quarterly revenues are $14.9M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Enanta Pharmaceuticals's net income of -$22.6M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.92x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -151.71% compared to Enanta Pharmaceuticals's net margin of --. Enanta Pharmaceuticals's return on equity of -74.26% beat Oragenics's return on equity of --.

Enanta Pharmaceuticals has a consensus price target of $14.83, signalling upside risk potential of 154.87%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 420.83%. Given that Oragenics has higher upside potential than Enanta Pharmaceuticals, analysts believe Oragenics is more attractive than Enanta Pharmaceuticals.

Enanta Pharmaceuticals has a beta of 0.811, which suggesting that the stock is 18.902% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals quarterly revenues are $14.9M, which are larger than Oragenics quarterly revenues of --. Enanta Pharmaceuticals's net income of -$22.6M is lower than Oragenics's net income of -$2.2M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.92x versus 1.84x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -151.71% compared to Enanta Pharmaceuticals's net margin of --. Enanta Pharmaceuticals's return on equity of -74.26% beat Plus Therapeutics's return on equity of --.

Enanta Pharmaceuticals has a consensus price target of $14.83, signalling upside risk potential of 154.87%. On the other hand Plus Therapeutics has an analysts' consensus of $9.83 which suggests that it could grow by 3277.99%. Given that Plus Therapeutics has higher upside potential than Enanta Pharmaceuticals, analysts believe Plus Therapeutics is more attractive than Enanta Pharmaceuticals.

Enanta Pharmaceuticals has a beta of 0.811, which suggesting that the stock is 18.902% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.878, suggesting its less volatile than the S&P 500 by 12.185%.

Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals quarterly revenues are $14.9M, which are larger than Plus Therapeutics quarterly revenues of --. Enanta Pharmaceuticals's net income of -$22.6M is lower than Plus Therapeutics's net income of -$2.9M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.92x versus 0.36x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -151.71% compared to Enanta Pharmaceuticals's net margin of --. Enanta Pharmaceuticals's return on equity of -74.26% beat Theriva Biologics's return on equity of --.

Enanta Pharmaceuticals has a consensus price target of $14.83, signalling upside risk potential of 154.87%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1438.46%. Given that Theriva Biologics has higher upside potential than Enanta Pharmaceuticals, analysts believe Theriva Biologics is more attractive than Enanta Pharmaceuticals.

Enanta Pharmaceuticals has a beta of 0.811, which suggesting that the stock is 18.902% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Enanta Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enanta Pharmaceuticals pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Enanta Pharmaceuticals quarterly revenues are $14.9M, which are larger than Theriva Biologics quarterly revenues of --. Enanta Pharmaceuticals's net income of -$22.6M is lower than Theriva Biologics's net income of -$4.3M. Notably, Enanta Pharmaceuticals's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enanta Pharmaceuticals is 1.92x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.